EURORDIS European Patient Advocacy Group (ePAG) Constitution and Rules of Procedure  
(09 May 2019)

Table of Contents

EURORDIS European Patient Advocacy Group (ePAG) Constitution and Rules of Procedure .......... 1  
Common Specifications and Definitions .................................................................................. 3  
1. Introduction ...................................................................................................................... 3  
2. Preamble .......................................................................................................................... 4  
3. Amendment of ePAG Constitution and Rules of Procedure ........................................... 4  
4. Definitions ....................................................................................................................... 4  
Part 1: Founding Principles & Membership ......................................................................... 7  
1. Mandate ........................................................................................................................... 7  
2. European Patient Advocacy Groups (ePAGs) ................................................................... 7  
   i. Function and Remit of European Patient Advocacy Groups (ePAGs) .............................. 7  
3. ePAG Community ........................................................................................................... 8  
4. ePAG Advocate .............................................................................................................. 9  
   i. ePAG Advocates Role .................................................................................................. 9  
5. EURORDIS ...................................................................................................................... 10  
6. Transversal Patient Involvement ..................................................................................... 11  
   i. ePAG Steering Committee .......................................................................................... 11  
   ii. ePAG Transversal Topic-Based Groups (TTGs) ........................................................... 11  
Part 2: ePAG Rules of Procedure ....................................................................................... 12  
1. Establishment of European Patient Advocacy Groups ..................................................... 12  
2. ePAG Community Registration ...................................................................................... 12  
3. Application for new ePAG Advocates ............................................................................. 12  
4. Process of Approval for ePAG Community and ePAG Advocates ................................ 13  
5. Time commitment ............................................................................................................ 13
6. European Patient Advocacy Groups (ePAG) Steering Committee ........................................... 13
7. Disputes ........................................................................................................................................ 13
8. Conflicts of interest ...................................................................................................................... 14
9. Resignation of ePAG Advocates ................................................................................................... 14
10. Termination of role of ePAG Advocates ...................................................................................... 14
11. Renewal of ePAG Advocates Term ............................................................................................... 15
Annex I: Mediation Process .................................................................................................................. 16
Annex II: Request for Mediation Form ................................................................................................. 17
1. Introduction

European Reference Networks (ERNs) have been established on the founding principle of patient empowerment and involvement\(^1\), to improve access, safety and quality of diagnosis, care and treatment for people living with a rare or complex condition, or who require highly specialist interventions that call for the centralisation of cases, expertise and resources\(^2\). Patient advocates are experts by experience and their participation in ERNs is recognised as integral to represent patients’ needs and perspectives in network discussions and activities, and ultimately to support ERNs delivery on their goals.

The EUCERD ERN Recommendations and Addendum\(^3\), formally recognised the critical and integral role that patient representatives play as formal members of the decision and opinion making structures of ERNs. As experts by experience, rare disease patients draw on their knowledge of living with a rare disease, enhancing the expertise in clinical services and research networks, building a critical mass of knowledge to tackle the EU rare disease public health priority.

The European Commission led and supported Member States to organise the rare disease clinical and research community to create European Reference Networks through a Call for Applications for ERN and their Healthcare Provider Members (HCP). However, the EC Call for Applications only focused on organising the Full HCP Members under ERNs and not the organisation of the patient community. EURORDIS and the rare disease patient community have worked together for over a decade to develop the concept of European Reference Networks as patient centred networks, rooting patient involvement at all levels and across all ERNs and building on the experience and recognition gained from the pilot ERNs that recognised and valued patient representatives’ contribution in rare disease networks.

In 2016, EURORDIS in collaboration with the European rare disease community established 24 European Patient Advocacy Groups (ePAGs) as forums to optimise the involvement of patient representatives of the rare disease community in the 24 ERNs. Each ePAG corresponds to the scope of one of the 24 ERNs, aligning patient organisations and clinicians, experts and researchers working on the same rare or complex disease or highly specialised intervention. These groups are composed by appointed patient advocates, some of which were elected in 2016 and others have been co-opted.

---

\(^1\) OJ L 174, 17.5.2014, p. 73, Commission Delegated Decision 2014/286/EU of 10 March 2014 setting out criteria and conditions that European Reference Networks and healthcare providers wishing to join a European Reference Network must fulfil, Annex 2(2b)

\(^2\) OJ L 174, 17.5.2014, p. 73, Commission Delegated Decision 2014/286/EU of 10 March 2014 setting out criteria and conditions that European Reference Networks and healthcare providers wishing to join a European Reference Network must fulfil

\(^3\) European Union Committee of Experts for Rare Diseases Addendum: Rare Disease European Reference Networks (2015)
2. Preamble

To organise and coordinate patient involvement in ERNs, this document sets out:

a. The function and remit of the European Patient Advocacy Groups (ePAGs) and the criteria that patient representatives must fulfil to join an ePAG (Part 1 - Founding Principles and Membership) and;

b. The process for establishing and governing ePAGs, the engagement of Patient Organisations with ePAGs and the recruitment process of ePAG Advocates (Part 2 - ePAG Rules of Procedure);

The principles and approach described in this document sets out the overall framework for patient involvement into ERNs, ensuring unity, solidarity and equity of patient representation from the rare disease community. Recognising the heterogeneous nature of the rare disease patient community and their diverse needs, this framework for patient involvement into ERNs can be locally adapted to best meet the specific needs of each ePAG Community.

3. Amendment of ePAG Constitution and Rules of Procedure

The ePAG Constitution and Rules of Procedure will be reviewed by the ePAG Steering Committee on an annual basis to ensure they remain fit for purpose and will be adopted by the EURORDIS Board of Directors.

4. Definitions

a. Patient Organisations (PO): Patient Organisation that is registered in Europe, either at a national or European level, and which is active in advocacy work in Europe.

b. European Patient Advocacy Group (ePAG): A patient group, specific to each European Reference Network, composed by patient advocates established by EURORDIS to optimise patient involvement in the ERNs’ decisions and activities. Some ERNs have formally recognised these groups as part of their governance structure.

c. ePAG Advocate: A patient representative to a specific European Reference Network who is active in the ERN governance structure including its working groups.

d. ePAG Chair: Appointed patient representative(s) who chair(s) the ePAG and is a formal representative of the ERN Board.

e. ePAG Community: The group of all Patient Organisations, members and non-members of EURORDIS, that have expressed their interest and have registered with EURORDIS to be engaged with a specific European Reference Network.

f. ePAG Steering Committee: Transversal Steering Committee composed by nominated ePAG Advocates from the 24 ePAGs, to provide strategic advice, share experience and knowledge from the 24 ERNs.
g. **ePAG Transversal Topic Based Groups:** Transversal peer learning groups composed by ePAG Advocates dedicated to a specific topic, e.g.: clinical guidelines and outcomes, research and registries, eHealth, training and education. These groups are aligned with the Network Coordinators’ Transversal Working Groups (please see definition below).

h. **EURORDIS ERN Team:** EURORDIS internal team that supports the development and coordination of patient involvement into ERNs, providing capacity building, advocacy and communication specifically on ERNs activities.

i. **EUCERD:** European Union Committee of Experts on Rare Diseases established to support EU policy on rare diseases, and specifically provide policy guidance on the effective implementation of the 2008 EU Commission Communication on Rare Diseases and the 2009 Council (of the European Union) Recommendation on action in the field of rare diseases. In 2013 it was replaced by the European Commission Expert Group on Rare Diseases (CEG –RED) whose mandate terminated in 2016. The EUCERD and CEG-RD brought together representatives from: the 28 EU Member States, Iceland, Norway, Switzerland, the EU Commission, the Committee for Orphan Medicinal Products of the EMA, industry, academia, eight individual experts as well as eight patient advocates.

j. **Board of Member States (BoMs):** A governing body consisting of representatives from Member States across EU Member States and European Economic Area responsible for the formal designation of European Reference Networks as provided in the Commission Implementing Decision 2014/287/EU. The Board of Member States (BoMs) has the responsibility of approving European Reference Networks (ERNs).

k. **European Reference Network (ERN):** A group of highly specialised healthcare providers that have been awarded with the membership of a given Network. Networks focus on rare or low prevalence and complex disease(s), condition(s) or highly specialised intervention(s) as regulated by article 12 of the Directive 2011/24/EU on patients’ rights in cross-border healthcare.

l. **Board of the Network:** The coordination body for each Network responsible for its governance, as foreseen in the Commission Delegated Decision 2014/286/EU (Annex I). All members of the Network must be represented on the Board.

m. **ERN Core Networks:** ERNs are thematic networks covering a number of rare or complex diseases and/or highly specialised interventions or surgery, as defined in their ERN application scope. Each ERN is structured differently to reflect the needs and grouping of their rare diseases into a number of ‘Core Networks’, also known as Disease Specific Networks or Sub-Thematic Working Groups, (e.g.: ERN-Lung has 9 core networks including Cystic Fibrosis, Pulmonary Hypertension, etc). Each one of these networks have a clinical committee or board of experts in that specific field to coordinate and lead the ERN activities specific to this disease area.

---

4 OJ L 174, 17.5.2014, p. 79, Commission Implementing Decision 2014/287/EU of 10 March 2014 setting out criteria for establishing and evaluating European Reference Networks and their Members and for facilitating the exchange of information and expertise on establishing and evaluating such Networks


6 OJ L 174, 17.5.2014, p. 74, Commission Delegated Decision 2014/286/EU of 10 March 2014 setting out criteria and conditions that European Reference Networks and healthcare providers wishing to join a European Reference Network must fulfil
n. **ERN Transversal Working Groups**: each ERN has identified a number of transversal working groups on topics and activities that are cross-cutting all their core networks.

o. **ERN Coordinator**: the person appointed as the Coordinator of the Network by the Member of a European Reference Network chosen as the coordinating Member as referred to in recital 3 and Article 4 of Delegated Decision 2014/286/EU.

p. **ERN Coordinators Group**: a working group that brings together the Coordinators of the 24 ERNs to discuss common technical matters.

q. **Healthcare Provider (HCP) Member**: a centre of medical expertise / excellence or specialist team treating rare and complex diseases, who has been endorsed by their Member State as an expert centre, is in compliance with the criteria and conditions laid down in Article 5 of the Commission Delegated Decision (2014/286/EU) and has been awarded with the membership of a given network.

r. **Affiliated Partner**: Member States with no Member of a given Network may decide to designate healthcare providers with a special link to a given ERN, following a transparent and explicit procedure. Those providers might be designated as Associated National Centres focusing in the provision of healthcare, Collaborative National Centres focusing in the production of knowledge and tools to improve the quality of care or a National Coordination Hub who connects their national healthcare system with ERNs, coordinating information and referrals.
Part 1: Founding Principles & Membership

1. Mandate

Patient representatives and organisations are recognised by the European Commission Expert Group for Rare Disease, as integral to the strategic and operational delivery of European Reference Networks in rare diseases (RD ERN) and should play an active role in the networks’ decision and opinion-making structures\(^7\).

2. European Patient Advocacy Groups (ePAGs)

European Reference Networks are comprised of Healthcare Providers Members (HCPs) that have been assessed by the European Commission to be Full Members or Affiliated Partners of their respective ERN. HCP Members are experts for specific rare diseases or highly specialised interventions and organised under one of the 24 ERNs. There is no legal basis for patient representatives or organisations to be formal members in an ERN.

European Patient Advocacy Groups (ePAGs) are patient forums comprised of Patient Organisations (ePAG Community) wishing to engage in a specific ERN and their representatives (ePAG Advocates) are endorsed by their respective Patient Organisations, to be active in ERN activities and governance board and committees. Each European Reference Network has one European Patient Advocacy Group composed by ePAG Advocates.

Patient Organisations who wish to be involved in one of the ERNs may join an ePAG Community. Patient Organisations can endorse a named patient representative (ePAG Advocate) to act on their behalf and in the interests of the specific rare disease community covered by the scope of the ERN. Each ePAG Advocate must commit to fulfilling the remit described in Section 4 below and meet the requirements described in Section 3 (Part 2).

i. Function and Remit of European Patient Advocacy Groups (ePAGs)

ePAGs aim to represent the voice of patients within ERNs to ensure the needs of people living with a rare disease are included in the strategic and operational delivery of the network. ePAGs create a bridge between the ERN and the patient community, to ultimately ensure that ERN services can answer to the needs and expectations of rare disease patients and therefore improve access to high quality diagnosis, care and treatment.

ePAGs deliver these aims through their ePAG Advocates, who work together with the HCPs members of the ERN and undertake the following activities inside the ERN governance structures:

---

\(^7\) European Union Committee of Experts for Rare Diseases Addendum: Rare Disease European Reference Networks (2015)
• Contribute to the development of information for patients: treatment policies, good practice guidelines and care pathways to ensure they are patient centred by reflecting and meeting the needs of patients;
• Participate to the development of a monitoring process of the outcomes of the ERN;
• Support the network in the dissemination of information and communication to the wider patient community;
• Contribute to the development of research priorities and ensure they are informed by the needs of patients and families;
• Provide advice on ethical issues on the application of personal data protection rules, compliance of informed consent and handling of complaints;
• Engage with the appropriate patient communities for disease specific activities and projects.

Diagram: Patient involvement into each European Reference Network is organised at three levels as outlined in the example below.

3. ePAG Community

Joining an ePAG Community is open to all patient organisations that register to be active and engage in one of the ERNs. Each ePAG Community is comprised of Patient Organisations, members and non-members of EURORDIS established in Europe, that register to engage with a specific European Reference Network. Each Patient Organisation may designate a contact person to receive information and engage with the ePAG.

The ePAG Community is active within its wider patient community and communicates, engages and consults externally to the ERN, with their respective patient community, specifically:
• Communicating and disseminating ERN activities;
• Ensuring feedback on patient experience in the development of guidelines and pathways;
• Promoting the participation of their patient community in ERN activities.
4. ePAG Advocate

ePAG Advocates are active internally to the ERN, within the ERNs governance structures of network boards, committees and working groups. All patient advocates wishing to be involved in an ERN must have knowledge of the working group topic or experience of living with a rare disease that is included in the scope of that ERN.

Each ERN covers a thematic group of rare diseases or highly specialised interventions and is organised into multiple Core Networks. The thematic grouping of ERNs follows the EUCERD’s ERN Recommendation’s Addendum in their structure and focus. Each ERN Core Network has a committee, in which ePAG Advocates will be active on behalf of their patient organisation AND respective patient communities.

In addition, each ERN has ePAG Advocates who are formal members of the ERN Network Board or Executive Committee and who represent the ePAG in the Network Board discussions.

ePAG Advocates provide their support on a voluntary basis and are unpaid for their work in ERNs. The policy for travel reimbursement for patient involvement in ERNs is set out individually in each ERN. There is no one policy applied across all ERNs; however, travel and accommodation costs for patient representatives are normally covered by the ERN for their annual meeting.

i. ePAG Advocates Role

All ePAG Advocates agree to represent the wider patient community and perform the following role and activities:

- Assist the HCP Members within their ERN;
- Represent the voice of all patients within the ERNs ensuring that the needs of people living with a rare disease are included in the strategic and operational delivery of the network;
- Create a bridge between the ERN and the rare disease patient community to; ultimately, improve access to high quality diagnosis, care and treatment.
- Contribute to the development of patient information, treatment policies, good practice guidelines and care pathways;
- Support the network to disseminate information and communicate to the patient community;
- Contribute to the development of research priorities and ensure they are informed by the needs of patients and families;
- Provide advice on ethical issues, and balance patient and clinical needs appropriately;
- Ensure transparency in quality of care, safety standards, clinical outcomes and treatment;
- Ensure feedback of patient experience. Engage with the appropriate patient communities for disease specific activities and projects.
All ePAG Advocates commit to adhering to the following set of **core values**:

- Respecting the scope of the mission of the ERN Board, Executive Committee and working groups;
- Listening to the opinions and requests of others;
- Showing solidarity, mutual respect and support;
- Adhering to the principles of equity and social justice;
- Conducting themselves with professionalism in engaging with the clinical, research leads and fellow patient advocates;
- Committing to be active in the ERN and report regularly on their activities;
- Ensuring regular communication with their ePAG Community and different relevant stakeholders.

ePAG Advocates must declare any potential Conflict of Interest in formal meetings or activities and remain independent, irrespective of their personal situation, pathology, and/or association and pharmaceutical industries.

To ensure effective and coordinated action, ePAG Advocates will coordinate with their ERN Board, the ePAG Steering Committee and EURORDIS ERN team before communicating with the European Commission, the Board of Member States and the Network Coordinators Group on matters related to ERNs.

They also commit to adhere to the terms of the mediation agreement that may result from a mediation process that they voluntarily decide to initiate to solve a dispute, as described in Part 2, Section 8 and Annex I.

### 5. EURORDIS

EURORDIS will provide support to the establishment and operational delivery of ePAGs, ensuring that its vision, mission and core values are respected. Specifically, providing the ePAG Advocates with the necessary tools and training to support them in fulfilling their mission, ensuring regular communication and listening to their opinions.

EURORDIS will coordinate, administrate and support structuring of the patient community into ERNs and their respective ePAG, specifically:

- Engage with the ePAGs and support the recruitment of new ePAG Advocates when identified;
- Provide technical expertise on ERNs, research, digital health, medicine development, etc;
- Raise awareness and capacity building for patient representatives and wider community;
- Engage with National Alliances and European Federations and wider patient community;
- Be a mediator and arbitrator of issues.

EURORDIS has set up an internal ERN Team to support all patient advocates who are active in ERNs. EURORDIS ERN Team is led by EURORDIS Director for Healthcare & ERNs and EURORDIS staff.
members dedicated to support specific ePAGs, in addition this core team is supported by EURORDIS leads in Public Affairs, Therapeutic Development & Access, Research & Social Policy and Communication Team.

The EURORDIS ERN Team will specifically:

- Engage with the ePAG Steering Committee to canvass opinion and views to inform advocacy activities towards the European Commission, Member States and ERNs;
- Provide capacity building and training;
- Provide technical support on ERNs activities (e.g.: research and registries, clinical guidelines and outcomes, education and training, etc.);
- Support the administration and organization of patient representatives into ERNs.

6. Transversal Patient Involvement

i. ePAG Steering Committee

EURORDIS has set up an ePAG Steering Committee which is a transversal committee of ePAG Advocates from each of the 24 ePAGs. The ePAG Steering Committee’s role is to:

- Peer-learning from each other by sharing their experience and knowledge from being active in the 24 ERNs;
- Provide strategic advice to inform and prioritise advocacy activities on behalf of all ePAGs and inform on areas of support and training needs to focus EURORDIS support and advocacy activities based on their collective needs.

ePAG Advocates who are official members of the ePAG Steering Committee, may choose to become EURORDIS Volunteers and have an official permanent mandate to represent EURORDIS. As EURORDIS Volunteers they will have to adhere to the principles and obligations described in the EURORDIS Charter of Volunteers and report each year the time spent working for EURORDIS. Conversely, EURORDIS staff provide necessary support to help volunteers fulfil their mission. The monetary value corresponding to the time spent by EURORDIS volunteers will be taken into account in EURORDIS accounts as an in kind contribution. To formalise their designation, ePAG Advocates will have to send an email to EURORDIS ERN team expressing their interest to become a EURORDIS Volunteer.

ii. ePAG Transversal Topic-Based Groups (TTGs)

EURORDIS has set up transversal Topic-Based Groups. These are peer learning groups dedicated to a specific topic, e.g.: clinical guidelines and outcomes, research, digital health, training and education. The TTGs are open to ePAG Advocates who are active in their respective ERN transversal working groups for that specific topic.
Part 2: ePAG Rules of Procedure

1. Establishment of European Patient Advocacy Groups

ePAGs were launched in 2016 while the ERN network applications were being developed in answer to the EC Call for ERN Applications. The immediate and pressing priority for the patient community in developing ePAG forums was to ensure that there was sufficient patient capacity to support the establishment of ERNs and foster working partnerships with the clinical and research leads in the ERN formative years.

ePAGs range in size depending on the size and scope of their respective ERNs. However, the minimum level of patient representatives’ capacity for each ePAG is two ePAG Advocates per each of the ERN Core Networks that sit under the thematic structure of the 24 European Reference Networks. In addition, a minimum of two ePAG Advocates are appointed to be members of their ERN Network Board and each of the ERN Transversal Working Groups. The process for identifying patient representatives to be formal members of ERN Boards is specific to each ERN and detailed in the ERNs ‘rules of procedure’. These representatives have been agreed by the ERN Network Coordinator, their Network Board members and their ePAG.

ePAGs will initially run for a five-year term before undergoing a review and renewal process in parallel with the first evaluation of ERNs in 2021. This timeframe will allow the ePAGs to establish themselves, connect with the wider patient communities and be part of the development, planning and implementation phase of the ERNs.

2. ePAG Community Registration

To join an ePAG Community, and to collaborate, consult and be kept informed on the development of ERNs, a Patient Organisation should contact EURORDIS ERN team or register via the online registration portal and indicate which ERN grouping it wishes to be engaged with.

EURORDIS will inform the relevant ePAG and ERN management team about the new Patient Organisations who have expressed interest in registering to be engaged with an ERN and of new ePAG Advocate applications, on a continuous basis.

3. Application for new ePAG Advocates

Rare disease Patient Organisations, EURORDIS members and non-members established in Europe, may designate ePAG Advocates. Each of the 24 ePAGs coordinate the recruitment of patient representatives as ePAG Advocates. EURORDIS will engage with the ePAGs to identify gaps in patient representation in the ERNs and support to actively recruit new ePAG Advocates.

The eligibility criteria for ePAG Advocates are:
• To be officially endorsed by one or more Patient Organisation and/or a European Federation;
• To be experienced in living with the rare disease included under the scope of the ERN or hold relevant expertise corresponds to the scope of the ERN Transversal Working Groups.
• To agree to meet the criteria and conditions for ePAG Advocates outlined in the ePAG Constitution (see please Section 4, Part 1).
• To agree to adhere to the set of core values adopted in the ePAG Constitution (see please Section 4, Part 1).
• Able to speak fluent English (spoken and written).

4. Process of Approval for ePAG Community and ePAG Advocates

Enrolment of new Patient Organisations in the ePAG Community and approval of ePAG Advocates is through agreement in the ePAG and in consultation with the ERN Network Coordinator.

5. Time commitment

Patient representative involvement in an ERN is an important and unique opportunity to achieve a step-change in care for rare disease patients in Europe. Active involvement in an ERN requires a considerable investment in terms of time and workload for ePAG Advocates in order to achieve meaningful benefits for our community. ePAG Advocates are required to commit time to their role and is estimated as at a minimum two days per month. The estimate time commitment could be significantly higher for the patient advocates sitting in the Network Boards or joining an ERN transversal working group, due to the amount of workload required to deliver on their role. There will be patient advocates whose workload will be even bigger. It is recognised that for the patient community, it can be from time to time impossible to meet this level of commitment and every effort will be made to support patient representatives where necessary.

6. European Patient Advocacy Groups (ePAG) Steering Committee

EURORDIS will lead the development of an ePAG Steering Committee and provide administrative and technical support. Each ePAG will appoint two ePAG Advocates (lead and alternate) as their representatives on the Steering Committee. The ePAG Advocates appointed to sit on the ePAG Steering Committee will (ideally) be members of the ERN Board.

The ePAG Steering Committee will run for five years before named representatives are renewed.

7. Disputes

If a dispute arises between Patient Advocates in an ePAG, they commit in good faith to try to take steps to resolve the dispute together. They may seek advise from EURORDIS if needed by approaching the ERN team member that supports the ePAG group.

---

EURORDIS can endorse a patient representative on a temporary basis until the patient representative can be adopted by a patient organisation or a European Federation.
If the parties cannot settle the dispute in a satisfactory way, any of them may request EURORDIS to mediate by submitting a Request for Mediation Form. Having a dispute mediated by EURORDIS is a voluntary process. When EURORDIS receives a Request for Mediation form, a member of the EURORDIS ERN team will first contact the other party or parties involved and seek their agreement to mediate.

Once the agreement to mediate has been obtained from all parties involved, the mediation process will be conducted following the process described in Annex I. The parties commit to adhere to the terms of the mediation agreement that may result from a mediation process that they voluntarily decide to initiate to solve a dispute, as described in Part 2, Section 8 and Annex I.

Confidentiality will be guaranteed in any mediation activity in which EURORDIS is requested to engage, however the ERN Coordinator will be informed on a confidential basis in all cases. If mediation is inconclusive and the circumstances are untenable, agreement will be reached with the ERN Coordinator on the appropriateness of termination of the ePAG Advocate in the ERN.

In disputes involving clinicians and patients, an ERN Coordinator and the ePAG Chair can jointly ask EURORDIS to mediate if the dispute cannot be settled within the ERN. The same process described in Annex I will be used to mediate in these conflicts.

8. Conflicts of interest

ePAG Advocates must comply with their ERN conflict of interest policy.

9. Resignation of ePAG Advocates

ePAG Advocates can step down from the ePAG at any time through contacting EURORDIS and discussing their decision. EURORDIS will engage with the ePAGs to identify new ePAG Advocates when needed.

10. Termination of role of ePAG Advocates

Patient representative appointment in an ePAG comes to an end if:

- The ePAG Advocate sends a notice of temporary suspension or resignation to its ePAG and EURORDIS, or
- The ePAG decides, in discussion with EURORDIS and the ERN Coordinator, that it is in the best interests of the ePAG and ERN that the representative in question should be removed.
- Before the ePAG takes any decision to remove someone from being an ePAG Advocate they must:
  1. inform the ePAG Advocate and EURORDIS of the reasons why it is proposed to remove them, and
  2. give at least 1 month for mediation and any concerns raised to be addressed
11. Renewal of ePAG Advocates Term

ePAG Advocates and their appointment representation will be renewed in the last year of the ERNs five-year term. The process for renewal will be developed and agreed in 2021.
Annex I: Mediation Process

Initiate mediation

Send formal request to EURORDIS

Contact parties concerned separately and explain process

Submit mediation form

Gather summary of the dispute and her relevant docs

Organise separate one to one calls to review the facts

Mediation begins

Organise Joint mediation session (f2f or online)

Parties to send confirmation on facts by email to EURORDIS

Min content of Joint Mediation Session:
- explain again mediation process
- remind parties of their duty of confidentiality
- ask the parties to present the issues in dispute
- identify potential corrective measures

Agree on process?

Yes

Send formal request to EURORDIS

Contact parties concerned separately and explain process

No

Impasse*

Submit mediation form

Agree on process?

Yes

Organise Joint mediation session to agree on action plan

1st Draft Action Plan

Final Action Plan

3-month probationary period

Organise Final Joint mediation session

Impasse*

Settlement?

Yes

End of mediation process

Follow-up call 3 months after

Impasse*

Settlement?

No

Follow-up call 3 months after

*If mediation is inconclusive, agreement will be reached with the ERN Coordinator on the appropriateness of termination of the ePAG Advocate role in the ERN
Annex II: Request for Mediation Form

Having your dispute mediated by EURORDIS is a voluntary process. When EURODIS receives your Request for Mediation form, a member of the EURORDIS ERN team will contact the other parties and seek their agreement to mediate. You will receive copies of our communications to the other parties.

Once all parties have agreed to the process and mediation is initiated, the parties commit to adhere to the terms of the mediation agreement that may result.

Please fill out the form completely. **Missing information may delay the processing of your request.**

**Party seeking mediation:**

Name  
Surname  
Email address  
Telephone

Please provide a brief description of the dispute. Include a summary of what occurred, relevant dates, names and titles of all individuals involved, and the settlement requested (e.g. resignation of a Chair, selection of new ePAG Advocate or what type of solution you are seeking for).

Please provide the following information for all parties to the dispute:

Name  
Email address  
Telephone number

Please email this completed form to: ines.hernando@eurordis.org